Terms: = Brain cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
10 results:
1. The efficacy of selinexor (KPT-330), an xpo1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
[TBL] [Abstract] [Full Text] [Related]
3. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Lassman AB; Wen PY; van den Bent MJ; Plotkin SR; Walenkamp AME; Green AL; Li K; Walker CJ; Chang H; Tamir S; Henegar L; Shen Y; Alvarez MJ; Califano A; Landesman Y; Kauffman MG; Shacham S; Mau-Sørensen M
Clin Cancer Res; 2022 Feb; 28(3):452-460. PubMed ID: 34728525
[TBL] [Abstract] [Full Text] [Related]
4. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after xpo1 and BTK inhibition.
Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
[TBL] [Abstract] [Full Text] [Related]
5. Simultaneous targeting of xpo1 and BCL2 as an effective treatment strategy for double-hit lymphoma.
Liu Y; Azizian NG; Dou Y; Pham LV; Li Y
J Hematol Oncol; 2019 Nov; 12(1):119. PubMed ID: 31752970
[TBL] [Abstract] [Full Text] [Related]
6. xpo1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
[TBL] [Abstract] [Full Text] [Related]
7. Dual Inhibition of Bcl-2/Bcl-xL and xpo1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract] [Full Text] [Related]
8. A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group.
Margol AS; Yeo KK; Xia C; Onar A; Robison NJ; Freyer DR; Dhall G
J Neurooncol; 2018 Dec; 140(3):575-582. PubMed ID: 30173409
[TBL] [Abstract] [Full Text] [Related]
9. The xpo1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown
Wahba A; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 Aug; 17(8):1717-1726. PubMed ID: 29866745
[TBL] [Abstract] [Full Text] [Related]
10. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract] [Full Text] [Related]
